AKT2 activehuman, recombinant, , N-terminal His tag
Size: 10 µg
Description: Recombinant full-lengthhuman AKT2 was expressed by baculovirusinfection in Sf9 insect cells and thenactivated by GST-PDK1 in vitro. The geneaccession number is NM_001626.
Specific Activity: 5.9 pmol/min/μg. Theenzyme reaction is conducted in a buffercontaining 50 mM HEPES (pH7.5), 10 mMMgCl2, 1 mM EGTA, 200 μM ATP, 0.01%Brij-35, and 2 μM substrate (SER/THR 6,Invitrogen) at room temperature for 1 hour.
Application: Useful for the study ofenzyme kinetics, screening inhibitors, andselectivity profiling.
Fomulated in: 25 mM Tris-HCl, pH 8.0, 100mM NaCl, 0.05% Tween-20, 50% glycerol, and3 mM DTT.
Stability: >6 months at –80°C
References:1. Alessi et al., Current Biology 8: 69, 19982. Cohen et al., FEBS Lett. 410: 3, 1997
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
NaturalProteinStopsDeadlyHumanBrainCancerInMice
ScientistsfromJohnsHopkinsandfromtheUniversityofMilanhaveeffectivelyproventhattheycaninhibitlethalhumanbraincancersinmiceusingaproteinthatselectivelyinducespositivechangesintheactivityofcellsthatbehavelikecancerstemcells.ThereportispublishedinNature.
Themostcommontypeofbraincancer-glioblastoma-ismarkedbythepresenceofthesestem-cell-likebraincells,which,insteadoftriggeringthereplacementofdamagedcells,formcancertissue.Stemcells,unlikeallothercellsinthebody,arecapableofformingalmostanykindofcellwhentheright"signals"triggertheirdevelopment.
Fortheirtreatmentexperiment,theresearchersreliedonaclassofproteins,bonemorphogenicproteins,thatcauseneuralstem-cell-likeclusterstolosetheirstemcellproperties,whichinturnstopstheirABIlitytodivide.
Firsttheypretreatedhumanglioblastomacellswithbonemorphogenicprotein4(BMP4),theninjectedthesetreatedcellsintomousebrains.Inmiceinjectedwithcellsthatwerenotpretreated,large,invasivecancersgrew.InthemicewithBMP4-treatedcells,nocancersgrewatall.Threetofourmonthsafterinjection,allmicethatgotuntreatedcellsdied,andnearlyallmicewithBMP4-treatedcellswerealive.
Next,thescientistsdeliveredslow-releaseBMP4-containing"beads"directlyintomousebrainswithimplantedglioblastomacells.Micethatgotemptybeadsdevelopedlargemalignanttumorsanddied.MicewithBMP4beadssurvivedmuchlonger,and80percentsurvivedfourmonthsaftercancercellimplants.
"OurideaistotreatpatientswithBMP4orsomethinglikeitrightaftersurgerytoremoveglioblastomainhopesofpreventingtheregrowthofthecancerandimprovingsurvivaltime,"saysAlessandroOlivi,M.D.,directoroftheDivisionofNeurosurgicalOncologyatHopkinsandacontributortothestudy.
OlivisaysclinicalstudiesusingBMP4couldbeginwithinayearand,ifsuccessful,drugtherapiescouldbeavailabletothepublicwithinthreetofouryears.
"ThiswasproofoftheideathatBMPscouldstopglioblastomabydepletingthestem-cell-likepopulationthatfeedsit,"saysHenryBrem,M.D.,chairmanoftheDepartmentofNeurosurgeryatHopkinsandacollaboratorinthestudy."Thisopensexcitingdoorstofutureresearchintotreatmentsandtherapiesforsuchadevastatingdisease."
暂无品牌问答